远端胆管癌非手术治疗的研究进展

陈姗姗; 李威

doi:10.3969/j.issn.1001-5256.2021.07.053

远端胆管癌非手术治疗的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.07.053

陈姗姗,
李威^,

首都医科大学附属北京地坛医院肿瘤诊治中心, 北京 100000

基金项目:

首都卫生发展科研专项 (2020-2-2175);

北京市百千万人才工程培养资助项目

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：陈姗姗负责选题, 收集分析资料, 撰写文章; 李威指导撰写文章, 提供修改意见并最终定稿。

详细信息

通信作者:
李威, weili8989@ccmu.edu.cn

中图分类号: R735.8
计量
- 文章访问数: 436
- HTML全文浏览量: 293
- PDF下载量: 35
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-20
- 录用日期: 2021-02-18
- 出版日期: 2021-07-20

Research advances in non-surgical treatment of distal cholangiocarcinoma

Shanshan CHEN,
Wei LI^,

Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100000, China

Research funding:

Capital's Funds for Health Improvement and (CFH) (2020-2-2175);

Beijing Talents Project

摘要

摘要: 远端胆管癌是肝外胆管细胞癌的一种类型, 侵袭性高, 预后较差。由于早期检出率低, 大部分患者确诊时已是中晚期。随着近年来介入、消融、光动力等医疗技术不断改进, 化疗、靶向、免疫等药物治疗进一步研发, 非手术治疗方式在远端胆管癌综合治疗中的作用愈发受到关注。简述了远端胆管癌在局部治疗和系统治疗方面的研究进展, 归纳总结相关文献表明, 局部治疗可以解除胆道梗阻、减轻肿瘤负荷、提高生存质量; 系统治疗可以抑制肿瘤生长、减少术后复发、延长生存时间。根据患者个体化情况, 结合各种非手术治疗制订不同的综合诊治方案, 可以为不可切除远端胆管癌患者提供更多有效的治疗选择。
- 胆管上皮癌 /
- 综合疗法 /
- 预后
Abstract: Distal cholangiocarcinoma is a type of extrahepatic cholangiocarcinoma with high invasiveness and poor prognosis, and due to its low rate of early detection, most patients are in the advanced stage at the time of diagnosis. In recent years, with the continuous improvement of medical techniques such as interventional treatment, ablation, and photodynamic therapy and further development of drug therapies including chemotherapy, targeted therapy, and immunotherapy, the role of non-surgical treatment in the multimodality therapy for distal cholangiocarcinoma has attracted more and more attention. This article reviews the advances in local treatment and systematic therapy for distal cholangiocarcinoma and summarizes related articles. The analysis shows that local treatment can relieve biliary obstruction, alleviate tumor burden, and improve quality of life, while systemic therapy may inhibit tumor growth, reduce postoperative recurrence, and prolong survival time. An individualized multimodality treatment regimen should be developed based on various non-surgical treatment methods, so as to provide more effective treatment options for patients with unresectable distal cholangiocarcinoma.
- Cholangiocarcinoma /
- Combined Modality Therapy /
- Prognosis

HTML全文

参考文献(45)

[1]	HOYOS S, NAVAS MC, RESTREPO JC, et al. Current controversies in cholangiocarcinoma[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1461-1467. DOI: 10.1016/j.bbadis.2017.07.027.
[2]	LEE RM, MAITHEL SK. Approaches and outcomes to distal cholangiocarcinoma[J]. Surg Oncol Clin N Am, 2019, 28(4): 631-643. DOI: 10.1016/j.soc.2019.06.014.
[3]	KOMAYA K, EBATA T, SHIRAI K, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma[J]. Br J Surg, 2017, 104(4): 426-433. DOI: 10.1002/bjs.10452.
[4]	ZHOU Y, LIU S, WU L, et al. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factors[J]. Asian J Surg, 2017, 40(2): 129-138. DOI: 10.1016/j.asjsur.2015.07.002.
[5]	WITZIGMANN H, LANG H, LAUER H. Guidelines for palliative surgery of cholangiocarcinoma[J]. HPB (Oxford), 2008, 10(3): 154-160. DOI: 10.1080/13651820801992567.
[6]	NAGINO M, HIRANO S, YOSHITOMI H, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition[J]. Chin J Dig Surg, 2021, 20(4): 359-375. DOI: 10.3760/cma.j.cn115610-20210303-00107. NAGINO M, HIRANO S, YOSHITOMI H, 等. 胆道肿瘤临床实践指南(英文第三版)[J]. 中华消化外科杂志, 2021, 20(4): 359-375. DOI: 10.3760/cma.j.cn115610-20210303-00107.
[7]	MIURA F, SANO K, WADA K, et al. Prognostic impact of type of preoperative biliary drainage in patients with distal cholangiocarcinoma[J]. Am J Surg, 2017, 214(2): 256-261. DOI: 10.1016/j.amjsurg.2017.01.010.
[8]	TAKAHASHI Y, NAGINO M, NISHIO H, et al. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma[J]. Br J Surg, 2010, 97(12): 1860-1866. DOI: 10.1002/bjs.7228.
[9]	Chinese society of Clinical Oncology (CSCO) biliary tumor Expert Committee. Consensus of experts on diagnosis and treatment of biliary system tumor (2019 Edition)[J]. Chin Clin Oncol, 2019, 24(9): 828-838. DOI: 10.3969/j.issn.1009-0460.2019.09.014. CSCO胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9): 828-838. DOI: 10.3969/j.issn.1009-0460.2019.09.014.
[10]	SHARAIHA RZ, KHAN MA, KAMAL F, et al. Efficacy and safety of EUS-guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails: A systematic review and meta-analysis[J]. Gastrointest Endosc, 2017, 85(5): 904-914. DOI: 10.1016/j.gie.2016.12.023.
[11]	SOFI AA, KHAN MA, DAS A, et al. Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: A systematic review and meta-analysis[J]. Gastrointest Endosc, 2018, 87(4): 944-951. DOI: 10.1016/j.gie.2017.10.029.
[12]	WU TT, LI WM, LI HC, et al. Percutaneous intraductal radiofrequency ablation for extrahepatic distal cholangiocarcinoma: A method for prolonging stent patency and achieving better functional status and quality of life[J]. Cardiovasc Intervent Radiol, 2017, 40(2): 260-269. DOI: 10.1007/s00270-016-1483-2.
[13]	KIM EJ, CHUNG DH, KIM YJ, et al. Endobiliary radiofrequency ablation for distal extrahepatic cholangiocarcinoma: A clinicopathological study[J]. PLoS One, 2018, 13(11): e0206694. DOI: 10.1371/journal.pone.0206694.
[14]	STRAND DS, COSGROVE ND, PATRIE JT, et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma[J]. Gastrointest Endosc, 2014, 80(5): 794-804. DOI: 10.1016/j.gie.2014.02.1030.
[15]	SALGADO SM, GAIDHANE M, KAHALEH M. Endoscopic palliation of malignant biliary strictures[J]. World J Gastrointest Oncol, 2016, 8(3): 240-247. DOI: 10.4251/wjgo.v8.i3.240.
[16]	LAQUIERE A, BOUSTIERE C, LEBLANC S, et al. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma[J]. Surg Endosc, 2016, 30(3): 1242-1248. DOI: 10.1007/s00464-015-4322-7.
[17]	HORGAN AM, AMIR E, WALTER T, et al. Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30(16): 1934-1940. DOI: 10.1200/JCO.2011.40.5381.
[18]	BEN-JOSEF E, GUTHRIE KA, EL-KHOUEIRY AB, et al. SWOG S0809: A phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015, 33(24): 2617-2622. DOI: 10.1200/JCO.2014.60.2219.
[19]	GHAFOORI AP, NELSON JW, WILLETT CG, et al. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(3): 654-659. DOI: 10.1016/j.ijrobp.2010.06.018.
[20]	HYGHES MA, FRASSICA DA, YEO CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct[J]. Int J Radiat Oncol Biol Phys, 2007, 68(1): 178-182. DOI: 10.1016/j.ijrobp.2006.11.048.
[21]	FULLER CD, WANG SJ, CHOI M, et al. Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: A population-based analysis[J]. Cancer, 2009, 115(22): 5175-5183. DOI: 10.1002/cncr.24572.
[22]	CHOI JH, OH D, LEE JH, et al. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter[J]. Endoscopy, 2015, 47(11): 1035-1038. DOI: 10.1055/s-0034-1392150.
[23]	AMBLARD I, MERCIER F, BARTLETT DL, et al. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups[J]. Eur J Surg Oncol, 2018, 44(9): 1378-1383. DOI: 10.1016/j.ejso.2018.04.023.
[24]	HERNANDEZ DL, RESTREPO J, GARCIA MORA M. Peritoneal metastasis of cholangiocarcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at the instituto nacional de cancerología, Colombia[J]. Cureus, 2020, 12(1): e6697. DOI: 10.7759/cureus.6697.
[25]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
[26]	VALLE JW, FURUSE J, JITLAL M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials[J]. Ann Oncol, 2014, 25(2): 391-398. DOI: 10.1093/annonc/mdt540.
[27]	MIZUSAWA J, MORIZANE C, OKUSAKA T, et al. Randomized phase Ⅲ study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)[J]. Jpn J Clin Oncol, 2016, 46(4): 385-388. DOI: 10.1093/jjco/hyv213.
[28]	SHROFF RT, JAVLE MM, XIAO L, et al. Gemcitabine, cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6): 824-830. DOI: 10.1001/jamaoncol.2019.0270.
[29]	LAMARCA A, PALMER DH, WASSAN HS, et al. ABC-06 \| A randomised phase Ⅲ, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy[J]. J Clin Oncol, 2019, 37: 4003.
[30]	PRIMROSE JN, FOX RP, PALMER DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5): 663-673. DOI: 10.1016/S1470-2045(18)30915-X.
[31]	NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375.
[32]	MONTAL R, SIA D, MONTIRONI C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 73(2): 315-327. DOI: 10.1016/j.jhep.2020.03.008.
[33]	LOEFFLER MA, HU J, KIRCHNER M, et al. miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis[J]. J Pathol, 2020, 252(3): 239-251. DOI: 10.1002/path.5514.
[34]	DRILON A, SIENA S, OU SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor Entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1)[J]. Cancer Discov, 2017, 7(4): 400-409. DOI: 10.1158/2159-8290.CD-16-1237.
[35]	DOEBELE RC, DRILON A, PAZ-ARES L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2): 271-282. DOI: 10.1016/S1470-2045(19)30691-6.
[36]	LE DT, DURHAM JN, SMITH KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413. DOI: 10.1126/science.aan6733.
[37]	ABOU-ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. DOI: 10.1016/S1470-2045(20)30109-1.
[38]	ABOU-ALFA GK, MACARULLA T, JAVLE MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 796-807. DOI: 10.1016/S1470-2045(20)30157-1.
[39]	LEE J, PARK SH, CHANG HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2012, 13(2): 181-188. DOI: 10.1016/S1470-2045(11)70301-1.
[40]	CHANG J, GU YC, LI XC. advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma[J]. Chin J Dig Surg, 2021, 20(2): 250-254. DOI: 10.3760/cma.j.cn115610-20210122-00037. 长江, 顾轶超, 李相成. 胆管癌免疫检查点抑制剂治疗研究进展[J]. 中华消化外科杂志, 2021, 20(2): 250-254. DOI: 10.3760/cma.j.cn115610-20210122-00037.
[41]	KANG J, JEONG JH, HWANG HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: Tumor proportion score as a potential biomarker for response[J]. Cancer Res Treat, 2020, 52(2): 594-603. DOI: 10.4143/crt.2019.493.
[42]	LEE SH, LEE HS, LEE SH, et al. Efficacy and safety of pembrolizumab for gemcitabine/cisplatin-refractory biliary tract cancer: A multicenter retrospective study[J]. J Clin Med, 2020, 9(6): 1769. DOI: 10.3390/jcm9061769.
[43]	KIM RD, CHUNG V, ALESE OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6): 888-894. DOI: 10.1001/jamaoncol.2020.0930.
[44]	FENG K, LIU Y, ZHAO Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: Results from a phase Ⅱ study[J]. J Immunother Cancer, 2020, 8(1): e000367. DOI: 10.1136/jitc-2019-000367.
[45]	XIE C, DUFFY AG, MABRY-HRONES D, et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer[J]. Hepatology, 2019, 69(5): 2048-2060. DOI: 10.1002/hep.30482.